Clinical Core - Pharmacogenomics of Statin Therapy (POST)

临床核心 - 他汀类药物治疗的药物基因组学 (POST)

• 批准号: 8934880
• 负责人: Carlos Iribarren
• 金额: $ 49.11万
• 依托单位: CHILDREN'S HOSPITAL & RES CTR AT OAKLAND
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8934880
• 关键词: Adopted; Adult; Adverse effects; Aging; Biomedical Research; California; Caring; Cell model; Clinical; Clinical Research; Cohort Studies; Collection; Computerized Medical Record; Coronary; DNA; Data; Data Set; Diabetes Mellitus; Disease; Electronic Health Record; Environment; Epidemiologic Studies; Event; Exposure to; Feces; Future; Genes; Genotype; Group Practice; Guidelines; Health; Human; In Vitro; Individual; Informatics; Lipids; Medical; Medical Electronics; Metabolic; Molecular; Myopathy; Participant; Patients; Pharmacogenomics; Pharmacologic Substance; Pharmacy facility; Plasma; Population; Population Heterogeneity; Recording of previous events; Records; Recruitment Activity; Research; Resources; Role; Sampling; Simvastatin; Site; Stroke; Study Subject; System; Variant; Whole Blood; adverse outcome; base; biobank; c new; clinical practice; cohort; database query; design; exome; follow-up; genetic analysis; genetic epidemiology; genetic information; genome wide association study; genome-wide; health care delivery; healthy aging; lymphoblastoid cell line; member; programs; prospective; response; socioeconomics; transcriptomics

CLINICAL CORE: PROJECT SUMMARY The Clinical Core at the Division of Research, Kaiser Permanente of Northern California (KPNC) is a key component of the overall POST Center. It serves a vital role by providing all the human participants for Project 1, and all the genotypic data, phenotypic data, and DNA samples to Project 3. The aims of the POST Clinical Core are: 1) To obtain whole blood and plasma from KPNC statin users with a) a major adverse coronary event (MACE, N=124) while on treatment, b) statin-induced myopathy (N=124), c) new onset diabetes (N=124), and d) three sets of 124 matched controls (N=372) for the studies in Project 1 (“Molecular Determinants of Statin Efficacy and Adverse Effects using Cellular Models”, Drs. Medina and Krauss); 2) With Project 3 (“Genome-wide Association Study of Statin Response and its Consequences”, Dr. Risch), create a dataset of medical and pharmacy information relevant to statin effects on lipids, MACE, stroke, statin-induced myopathy and new onset diabetes from the electronic medical records of patients in the GERA cohort; and 3) Provide DNA samples from selected statin users within the GERA cohort (n=2,517) and within the extended Kaiser Permanente Research Program on Genes, Environment, and Health (RPGEH) biorepository (n=843) to Project 3 for follow-up genetic analysis of candidate loci identified throughout the Center's research program.

临床核心：项目总结 北方加州Kaiser Permanente（KPNC）研究部的临床核心是一个关键 整个POST中心的组成部分。它通过为Project提供所有人类参与者而发挥着至关重要的作用 1，以及项目3的所有基因型数据、表型数据和DNA样本。POST临床的目的 核心是：1）从KPNC他汀类药物使用者中获得全血和血浆，a）严重不良冠状动脉粥样硬化性心脏病 治疗期间发生的事件（MACE，N=124），B）他汀类药物诱导的肌病（N=124），c）新发糖尿病 （N=124），和d）三组124个匹配对照（N=372），用于项目1（“分子生物学”）中的研究。 使用细胞模型的他汀类药物疗效和不良反应的决定因素”，Medina和Krauss博士）; 2） 项目3（“他汀类药物反应及其后果的全基因组关联研究”，Risch博士），创建一个 与他汀类药物对血脂、MACE、卒中、他汀类药物诱导的 来自GERA队列中患者的电子病历的肌病和新发糖尿病;以及3） 提供来自GERA队列（n= 2，517）和扩展队列中选定他汀类药物使用者的DNA样本。 Kaiser Permanente基因、环境和健康研究计划（RPGEH）生物储存库（n=843）， 项目3：对中心整个研究计划中确定的候选基因座进行后续遗传分析。